By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10th, 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an … Read more
By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Open Label Extension Initial Readout Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported preliminary results from its open label extension (OLE) portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long-term safety profile and improving efficacy over the one-year observation period. The schizophrenia candidate … Read more
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial had two parts: … Read more
By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive … Read more
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more
